Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Aminophylline, Furosemide.
- Who it may be relevant to
- Registry conditions: Diuretic Effect, Aminophylline, Furosemide, Cardiac Surgical Procedures. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparison Between the Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures: A Randomized Controlled Trial
Overview
This work aims to investigate the diuretic effect of Aminophylline in comparison to Furosemide in adult patients undergoing cardiac surgical procedures.
Detailed description
Acute Kidney injury (AKI) is a serious and common complication after either adult or pediatric cardiac surgery.
The results of a recent meta-analysis suggested that loop diuretics (furosemide) may reduce postoperative creatinine clearance, whereas aldosterone agonists (spironolactone) increase the incidence of cardiac surgery-associated acute kidney injury (CSA-AKI). Diuretics are not recommended for the prevention of AKI, but loop diuretics may be used for the management of volume overload Aminophylline in cardiac surgery can reduce the frequency of AKI and could be used in the prevention of AKI as a safe and efficient modality in high-risk patients.
Interventions
- Drug Aminophylline
Patients will receive Aminophylline. - Drug Furosemide
Patients will receive furosemide.
Primary outcome measures
- Measurement of urine output [Time frame: Two hours after cardiopulmonary bypass]
Secondary outcome measures (6)
- Measurement of urine output at completion of cardiopulmonary bypass [Time frame: 48 hours after cardiopulmonary bypass]
- Urea level [Time frame: 48 hours after cardiopulmonary bypass]
- Creatinine level [Time frame: 48 hours after cardiopulmonary bypass]
- Lactate level [Time frame: 48 hours after cardiopulmonary bypass]
- Estimated Glomerular Filtration Rate (eGFR) [Time frame: 48 hours after cardiopulmonary bypass]
- Measurement of fluid balance [Time frame: 48 hours after cardiopulmonary bypass]
Eligibility criteria
Inclusion criteria
- Age from 18-65 years.
- Both sexes.
- All adult patients presenting for elective cardiac surgical procedures performed on cardiopulmonary bypass (Coronary artery bypass surgery, Cardiac valve repair and/or replacement, Repair of large septal defects, Repair and/or palliation of congenital heart defects, Transplantation, surgery of thoracic aneurysms.).
- Body mass index (BMI) ranged between 20 and 40 kg/m2.
Exclusion criteria
- Sensitivity or contraindication to Aminophylline or furosemide
- Stage-5 chronic kidney disease (CKD) \[Glomerular filtration rate (GFR) of less than 15 mL/min\].
- The presence of both factors (GFR less than 60 mL/min and albumin greater than 30 mg per gram of creatinine) along with abnormalities of kidney structure or function for greater than three months signifies chronic kidney disease.
- Recipients of dialysis before surgery.
- Recipients of solid-organ transplantation before surgery.
- Emergency cardiac surgical procedures (e.g. left main coronary artery bypass graft, stuck valves, etc).
- Patient refusal.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Cairo University — Cairo
Identifiers
NCT: NCT07348510 · MD-258-2024